KeyBanc Upgrades LivaNova to Overweight, Sees 27% Upside as MedTech Valuations Normalize
KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.